{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine G cdc42 : Questions médicales les plus fréquentes",
"headline": "Protéine G cdc42 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine G cdc42 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-05-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine G cdc42"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines G rho",
"url": "https://questionsmedicales.fr/mesh/D020741",
"about": {
"@type": "MedicalCondition",
"name": "Protéines G rho",
"code": {
"@type": "MedicalCode",
"code": "D020741",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.338.400.700"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine G cdc42",
"alternateName": "cdc42 GTP-Binding Protein",
"code": {
"@type": "MedicalCode",
"code": "D020764",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jeong Woo Park",
"url": "https://questionsmedicales.fr/author/Jeong%20Woo%20Park",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Science, University of Ulsan, Ulsan, 44610, South Korea."
}
},
{
"@type": "Person",
"name": "Ming Huang",
"url": "https://questionsmedicales.fr/author/Ming%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Environmental Toxicology Graduate Program, University of California, Riverside, Riverside, California 92521, United States."
}
},
{
"@type": "Person",
"name": "Yinsheng Wang",
"url": "https://questionsmedicales.fr/author/Yinsheng%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of California, Riverside, Riverside, California 92521, United States."
}
},
{
"@type": "Person",
"name": "Natsumi Maruta",
"url": "https://questionsmedicales.fr/author/Natsumi%20Maruta",
"affiliation": {
"@type": "Organization",
"name": "Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia."
}
},
{
"@type": "Person",
"name": "Yuri Trusov",
"url": "https://questionsmedicales.fr/author/Yuri%20Trusov",
"affiliation": {
"@type": "Organization",
"name": "Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Plant trait and vegetation data along a 1314 m elevation gradient with fire history in Puna grasslands, Perú.",
"datePublished": "2024-02-21",
"url": "https://questionsmedicales.fr/article/38383609",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41597-024-02980-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "METTL14 affects UVB-induced human dermal fibroblasts photoaging via miR-100-3p biogenesis in an m",
"datePublished": "2024-02-21",
"url": "https://questionsmedicales.fr/article/38380598",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/acel.14123"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oldies, but goldies-preserved morphology and stability of antigenic determinants in decades-old cryosections of human m. vastus lateralis.",
"datePublished": "2024-01-07",
"url": "https://questionsmedicales.fr/article/38185737",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/joa.14003"
}
},
{
"@type": "ScholarlyArticle",
"name": "'I cannot see ahead': psychological distress, doomscrolling and dark future among adult survivors following M",
"datePublished": "2023-12-15",
"url": "https://questionsmedicales.fr/article/38102569",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-023-17460-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "The West of Scotland Cohort of Mitochondrial Individuals with the m.3243A>G Variant: Variations in Phenotypes and Predictors of Disease Severity.",
"datePublished": "2023-12-13",
"url": "https://questionsmedicales.fr/article/38108361",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3233/JND-230166"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines G",
"item": "https://questionsmedicales.fr/mesh/D019204"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines G monomériques",
"item": "https://questionsmedicales.fr/mesh/D020559"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines G rho",
"item": "https://questionsmedicales.fr/mesh/D020741"
},
{
"@type": "ListItem",
"position": 8,
"name": "Protéine G cdc42",
"item": "https://questionsmedicales.fr/mesh/D020764"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine G cdc42 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine G cdc42",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine G cdc42",
"description": "Comment diagnostiquer une dysfonction de cdc42 ?\nQuels tests sont utilisés pour cdc42 ?\nY a-t-il des biomarqueurs pour cdc42 ?\nQuels symptômes indiquent un problème avec cdc42 ?\nPeut-on détecter cdc42 dans des échantillons biologiques ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine G cdc42",
"description": "Quels sont les symptômes d'une mutation de cdc42 ?\nComment cdc42 affecte-t-il la cellule ?\nY a-t-il des signes cliniques associés à cdc42 ?\nCdc42 est-il lié à des maladies spécifiques ?\nQuels effets cdc42 a-t-il sur le cytosquelette ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine G cdc42",
"description": "Peut-on prévenir les mutations de cdc42 ?\nY a-t-il des mesures préventives pour les maladies liées à cdc42 ?\nComment le mode de vie influence-t-il cdc42 ?\nLes tests génétiques peuvent-ils prévenir des problèmes avec cdc42 ?\nY a-t-il des recommandations diététiques pour cdc42 ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine G cdc42",
"description": "Quels traitements ciblent cdc42 ?\nPeut-on utiliser des thérapies géniques pour cdc42 ?\nY a-t-il des médicaments pour moduler cdc42 ?\nComment la recherche avance-t-elle sur cdc42 ?\nLes traitements sont-ils efficaces contre cdc42 ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine G cdc42",
"description": "Quelles complications sont liées à cdc42 ?\nCdc42 peut-il entraîner des problèmes neurologiques ?\nY a-t-il des complications à long terme avec cdc42 ?\nComment cdc42 affecte-t-il le système immunitaire ?\nLes complications de cdc42 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine G cdc42",
"description": "Quels sont les facteurs de risque pour cdc42 ?\nL'exposition à des toxines affecte-t-elle cdc42 ?\nLes antécédents familiaux augmentent-ils le risque ?\nLe stress peut-il affecter cdc42 ?\nY a-t-il des groupes à risque pour cdc42 ?",
"url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=M+Phase+Cell+Cycle+Checkpoints&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de cdc42 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour cdc42 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'immunoblotting et la microscopie à fluorescence."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs pour cdc42 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour cdc42."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec cdc42 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la migration cellulaire et la morphogenèse peuvent être observées."
}
},
{
"@type": "Question",
"name": "Peut-on détecter cdc42 dans des échantillons biologiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, cdc42 peut être détecté dans des échantillons de tissus ou de cellules."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une mutation de cdc42 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations peuvent entraîner des troubles de la migration cellulaire et des malformations."
}
},
{
"@type": "Question",
"name": "Comment cdc42 affecte-t-il la cellule ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cdc42 régule la forme et le mouvement des cellules, influençant leur fonction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques associés à cdc42 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans le développement et la motilité cellulaire peuvent être observées."
}
},
{
"@type": "Question",
"name": "Cdc42 est-il lié à des maladies spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de cdc42 sont associées à des cancers et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Quels effets cdc42 a-t-il sur le cytosquelette ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cdc42 joue un rôle clé dans la régulation du cytosquelette, influençant la forme cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les mutations de cdc42 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention des mutations génétiques est complexe et dépend de facteurs environnementaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les maladies liées à cdc42 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques peuvent aider à évaluer le risque de maladies liées à cdc42."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il cdc42 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de maladies associées à cdc42."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des problèmes avec cdc42 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les porteurs de mutations de cdc42."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques pour cdc42 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais n'affecte pas directement cdc42."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent cdc42 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de cdc42 sont en cours de développement pour le cancer."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des thérapies géniques pour cdc42 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger les mutations de cdc42."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments pour moduler cdc42 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des composés chimiques sont en cours d'évaluation pour moduler l'activité de cdc42."
}
},
{
"@type": "Question",
"name": "Comment la recherche avance-t-elle sur cdc42 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche se concentre sur les inhibiteurs et les voies de signalisation associées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre cdc42 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements dépend du type de maladie et de la mutation spécifique."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à cdc42 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles du développement et des cancers."
}
},
{
"@type": "Question",
"name": "Cdc42 peut-il entraîner des problèmes neurologiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de cdc42 sont associées à des troubles neurologiques dans certains cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme avec cdc42 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications à long terme peuvent inclure des cancers et des malformations congénitales."
}
},
{
"@type": "Question",
"name": "Comment cdc42 affecte-t-il le système immunitaire ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cdc42 peut influencer la réponse immunitaire, mais les effets varient selon les contextes."
}
},
{
"@type": "Question",
"name": "Les complications de cdc42 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cdc42 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des influences environnementales."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines affecte-t-elle cdc42 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines toxines environnementales peuvent influencer l'expression de cdc42."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter cdc42 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut influencer la signalisation cellulaire, y compris celle de cdc42."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour cdc42 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les individus avec des mutations génétiques spécifiques sont à risque accru."
}
}
]
}
]
}
Alpine grassland vegetation supports globally important biodiversity and ecosystems that are increasingly threatened by climate warming and other environmental changes. Trait-based approaches can supp...
Exposure to ultraviolet radiation can lead to skin photoaging, which increases the risk of skin tumors. This study aims to investigate how microRNA m...
Fibre typing by immunohistochemistry on cryosections from human skeletal muscle biopsies is an essential tool in the diagnosis and research of muscular diseases, ageing, and responses to exercise trai...
The earthquakes, which occurred on 6 February 2023, affecting a total of eleven provinces in Türkiye, with magnitudes of 7.7 and 7.6, and killing around 50,000 people, caused the greatest loss of life...
In this research, an analytical cross-sectional study was conducted by applying face-to-face and online questionnaires to 402 adult individuals who had experienced the earthquake. The Depression, Anxi...
The results revealed that the participants had very high levels of future anxiety and moderate levels of doomscrolling after the earthquake. Although their psychological distress levels were relativel...
Individuals are more exposed to negative news streams in negative life events that occur beyond their control and they need to search for information. Increased levels of depression, anxiety and stres...
The m.3243A>G variant is the commonest mitochondrial (mt) DNA pathogenic variant and a frequent cause of mitochondrial disease. Individuals present with a variety of clinical manifestations from diabe...
This project aimed to identify patients with confirmed mt.3243A>G-related mitochondrial disease attending the Muscle Clinic at Queen Elizabeth University Hospital in Glasgow. We explored potential cor...
Data were gathered from the West of Scotland electronic records. Phenotypes were ascertained by a clinician with expertise in mitochondrial disorders. Statistical analyses were applied to study relati...
Forty-six individuals were identified from 31 unrelated pedigrees. Maternally inherited diabetes and deafness was the prominent syndromic phenotype (48%). A significant association was found between o...
This m.3243 A > G patient cohort present with marked clinical heterogeneity. Urine and blood heteroplasmy levels are not reliable predictors of disease severity. HbA1c may be a novel predictor of dise...
Recently, bla...
Totally, 1005 complete sequences of clinical E. coli were collected from NCBI. Multilocus sequence typing (MLST) and antibiotic resistance genes screening were performed....
Feces (26.27%), urine (16.02%), and blood (8.26%) were shown to be the main sources of clinical E. coli isolates. The isolates belong to 153 STs and 26 clonal complexes (CCs). The most prevalent STs w...
E. coli has become increasingly rich in bla...
The spatial distribution and interactions of cells in the tumor immune microenvironment (TIME) might be related to the different responses of triple-negative breast cancer (TNBC) to immunomodulators. ...
The clinical, imaging, and prognosis data for 86 TNBC patients were retrospectively reviewed. CD3, CD4, CD8, Foxp3, PD-L1, and Pan-CK markers were stained by m-IHC. Particular cell spatial distributio...
The components of the TIME score were established by m-IHC and demonstrated positive prognostic value for TNBC (p = 0.0047, 0.039, <0.0001 for DMFS, RFS, and OS). The score was calculated from several...
We demonstrated that the m-IHC-based quantitative score and indicators related to the spatial distribution and interactions of cells in the TIME can aid in the accurate diagnosis of TNBC in terms of p...
Genetically modified macrophage infusion has been proven to be a novel treatment for cancer. One of the most important processes in macrophage-based therapy is the efficient transfer of genes. HIV-1-d...
Non-alcoholic steatohepatitis (NASH) is a prevalent metabolic disease, characterized by the hepatic steatosis, inflammation, and fibrosis, which is lack of effective treatment currently. Protectin D1 ...
Two new species of the genus Yukikoa M. Sat, 1976 are described from Honshu, Japan: Y. mashimai sp. nov. from Niigata Prefecture and Y. nishimotoi sp. nov. from Fukui Prefecture. A revised key to the ...